Skyline Vet Pharma was co-founded by animal health and animal biology industry veterans
Companion animals (dogs and cats in particular) play an important part in the lives of many American families and others around the world. There are more than 150 million dogs and cats in
Treatment compliance remains one of the major challenges in modern veterinary medicine. The best therapy is worthless if pet owners cannot or do not administer prescribed drugs to their animals. Furthermore, the consequences of poor compliance, including increased cost of treatment, recurrences and relapses of the poorly treated disease, selection for antibiotic resistance, and unnecessary pain and suffering can be devastating. Palatable products, ease of dose administration and less frequent dosing will increase pet-owner bonding, which is a major factor in the commercial success of companion animal health products.
“The companion animal health industry is seeking innovative solutions for pet owners and the animals they care for,” said
Skyline Vet Pharma uses proven, in-licensed delivery technologies to reformulate known drugs not yet approved for use in animal health, thereby creating novel combination products for established markets. The company intends to bring several new products to the market over the next few years in three major therapeutic areas: pain/inflammation, cardiovascular disease and antimicrobials, areas that represent more than 60 percent of the prescriptions written by veterinarians.
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC